During this summer, on August 10, 2018, Jess was informing us (here) regarding the fact that her dad, dealing with Pancreatic Cancer Stage IV, will start a similar treatment approach as that successfully used by Marcos, and shortly discussed on this website (here).
Jess and I have exchanged a large amount of e-mails this year and consequently also became friends. She is extremely clever, and everything she does is carefully and extensively addressed leading to high quality work. Not only that her quality approach to what she is doing is impressive, but also her care for others is outstanding. Jess dose so much for helping her dad but she doesn’t stop there. And so recently, she did something very impressive: One of our good friends and visitors of this website needed some specific help for her dad, and Jess decided to fly to another continent for a day just to help our friend that she never met before. How impressive is that?
Status before the treatment, before August 2018:
– Jess’s dad was diagnosed with Stage IV pancreatic adenocarcinoma on Oct 3, 2017, with a primary tumor in the tail of the pancreas and several liver lesions. His CA 19-9 marker was 47.000 at diagnosis
– performed FOLFIRINOX until April 17th, 2018, and his CA 19-9 was 3.440
– removed oxaliplatin due to toxicity and continued with FOLFIRI but markers started to go fast up during the summer of 2018 (see graph below)
– during August 2018 decided to start low-dose Gemcitabine supported by many treatment approaches discussed on this website, and latter also introduced Abraxane
Results reported on October 2018:
CA 19-9 dropped by almost 95% over 2 months of treatment. Not only was the CA 19-9 response to this combined therapy much more rapid than the response to his first-line chemotherapy, in fact the CA 19-9 fell more rapidly than it rose during the two month “rest” period. Finally, a PET scan from Oct 10th, compared to one from July 25, showed decrease in intensity of the primary tumor and most importantly, “significant decrease in FDG uptake [from 8.1 to 4] within the large liver tumor, with mainly large photopenic region in the center of the lesion and a moderately FDG avid rim.” This result is consistent with necrosis in the body of the tumor.
Next to the chemotherapy, the treatment schedule included a few other substances expected to exert a strong pressure on the cancer cells including glycolisis inhibitors such as 2DG intravenous, Salinomycin, 3BP, Photo Dynamic Therapy (PDT), thyroid protocol but also diet approaches such as fasting, and various supplements and drugs.
As it can be seen from the graph kindly provided by Jess, the initial (low-dose) Gemcitabine dose could only slightly reduce the markers. Only after the introduction of the supportive therapies, the markers started to strongly decline. These impressive results clearly indicate the importance of the supportive therapies when dealing with advanced cancers.
In order to share her experience and help others, Jess started up a website. Please visit Jess’s website in order to get more details regarding the treatment schedule employed in treating her dad, as well as the related dose of chemotherapy and the supportive therapies used. In addition to that, Jess will continue to share on her website information regarding new treatment approaches she is researching and considering, so it would be a good idea to check her website from time to time for new content.
Unfortunately, Jess lost her dad the year after I wrote the above post – he got an infection (I think it was a port infection) that brought everything out of equilibrium. As he was brought to the hospital to address that infection the treatments discussed above had to be discontinued. After that infection and inflammation the tumors started to grow fast and could not be stopped in the short time available.
This site is not designed to and does not provide medical advice, professional diagnosis, opinion, treatment or services to you or to any other individual. Through this site and linkages to other sites, I provide general information for educational purposes only. The information provided in this site, or through linkages to other sites, is not a substitute for medical or professional care, and you should not use the information in place of a visit, call consultation or the advice of your physician or other healthcare provider. I am not liable or responsible for any advice, course of treatment, diagnosis or any other information, services or product you obtain through this site. This is just my own personal opinion regarding what we have learned on this road.
Please read an extended version of the Disclaimer here: https://www.cancertreatmentsresearch.com/?page_id=1794